| Autor: |
Fabian Rosing, Matthias Meier, Lea Schroeder, Simon Laban, Thomas Hoffmann, Andreas Kaufmann, Oliver Siefer, Nora Wuerdemann, Jens Peter Klußmann, Thorsten Rieckmann, Yvonne Alt, Daniel L. Faden, Tim Waterboer, Daniela Höfler |
| Jazyk: |
angličtina |
| Rok vydání: |
2024 |
| Předmět: |
|
| Zdroj: |
Microbiology Spectrum, Vol 12, Iss 7 (2024) |
| Druh dokumentu: |
article |
| ISSN: |
2165-0497 |
| DOI: |
10.1128/spectrum.00024-24 |
| Popis: |
ABSTRACT The incidence rate of human papillomavirus-driven oropharyngeal cancer (HPV-OPC) is increasing in countries with high human development index. HPV cell-free DNA (cfDNA) isolated from 3 to 4 mL blood plasma has been successfully used for therapy surveillance. A highly discussed application of HPV-cfDNA is early detection of HPV-OPC. This requires sensitive and specific cfDNA detection as cfDNA levels can be very low. To study the predictive power of pre-diagnostic HPV-cfDNA, archived samples from epidemiological cohorts with limited plasma volume are an important source. To establish a cfDNA detection workflow for low plasma volumes, we compared cfDNA purification methods [MagNA Pure 96 (MP96) and QIAamp ccfDNA/RNA] and digital PCR systems (Biorad QX200 and QIAGEN QIAcuity One). Final assay validation included 65 low-volume plasma samples from oropharyngeal cancer (OPC) patients with defined HPV status stored for 2–9 years. MP96 yielded a 28% higher cfDNA isolation efficiency in comparison to QIAamp. Both digital PCR systems showed comparable analytical sensitivity (6–17 copies for HPV16 and HPV33), but QIAcuity detected both types in the same assay. In the validation set, the assay had 80% sensitivity (n = 28/35) for HPV16 and HPV33 and a specificity of 97% (n = 29/30). In samples with ≥750 µL plasma, the sensitivity was 85% (n = 17/20), while in samples with |
| Databáze: |
Directory of Open Access Journals |
| Externí odkaz: |
|
